Skip to main content
Top

22-02-2018 | Ankylosing spondylitis | Article

Ischemic heart disease and ankylosing spondylitis—assessing the role of inflammation

Journal: Clinical Rheumatology

Authors: Michal Vinker Shuster, Omer Gendelman, Shmuel Tiosano, Doron Comaneshter, Arnon D. Cohen, Howard Amital

Publisher: Springer London

Abstract

To assess the association of ankylosing spondylitis (AS) and ischemic heart disease (IHD) compared to traditional cardiovascular (CV) risk factors. Primary care and hospital records of patients with AS were analyzed, using the largest health maintenance organization in Israel, the “Clalit” Health Services data. These patients were compared with age- and gender-matched controls regarding the proportion of IHD in a cross-sectional study. Parameters including socioeconomic status, body mass index (BMI), smoking habits, and coexistent medical conditions hypertension, hyperlipidemia, and diabetes mellitus (DM) - as well as the use of NSAIDs and anti-TNFs were also assessed. The study included 4076 AS patients compared to 20,290 age- and gender-matched controls without AS. The proportion of IHD was higher among AS patients as compared to controls (14.1 vs. 6.36%, respectively, p < 0.01) and patients treated with anti-TNFs had a lower risk for IHD compared to non-anti-TNF users. The proportion of hypertension, hyperlipidemia, DM, and smoking was also higher among AS patients. However, in multivariate analyses following adjustment to these risk factors, AS was not found to be associated with IHD nor anti-TNF therapy to be a protective factor. Patients with AS have more traditional CV risk factors, thus are in a higher risk for IHD. AS itself was not shown to be independently associated with IHD. These findings emphasize the multifactorial process leading to increased proportion of IHD among AS patients and the need for a stringent control of traditional risk factors in these patients.
Literature
1.
Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18CrossRefPubMedPubMedCentral
2.
El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22(6):554–560CrossRefPubMed
3.
Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology 53(4):650–657CrossRefPubMed
4.
Elewaut D, Matucci-Cerinic M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology. https://​doi.​org/​10.​1093/​rheumatology/​kep146
5.
Ozkan Y (2016) Cardiac involvement in ankylosing spondylitis. J Clin Med Res 8(6):427–430CrossRefPubMedPubMedCentral
6.
Momeni M, Taylor N, Tehrani M (2011) Cardiopulmonary manifestations of ankylosing spondylitis. Int J Rheumatol 2011:1–6CrossRef
7.
Bremander A, Petersson IF, Bergman S, Englund M (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 63(4):550–556. https://​doi.​org/​10.​1002/​acr.​20408 CrossRef
8.
Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed
9.
Nurmohamed MT, Van der Horst-Bruinsma I, Maksymowych WP (2012) Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep 14(5):415–421. https://​doi.​org/​10.​1007/​s11926-012-0270-6 CrossRefPubMed
10.
Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 63(4):557–563. https://​doi.​org/​10.​1002/​acr.​20364 CrossRef
11.
Chou C-H, Lin M-C, Peng C-L, Wu YC, Sung FC, Kao CH, Liu SH (2014) A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol 43(2):132–136. https://​doi.​org/​10.​3109/​03009742.​2013.​822097 CrossRefPubMed
12.
Mathieu S, Motreff P, Soubrier M (2010) Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 77(6):542–545CrossRefPubMed
13.
Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26(5):710–714CrossRefPubMed
14.
Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 109(2):171–176CrossRefPubMed
15.
Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592
16.
Murray CJL, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369(5):448–457CrossRefPubMed
17.
Wright KA, Crowson CS, Michet CJ, Matteson EL (2015) Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study. Arthritis Care Res 67(6):836–841. https://​doi.​org/​10.​1002/​acr.​22512 CrossRef
18.
Ahmed N, Prior JA, Chen Y, Hayward R, Mallen CD, Hider SL (2016) Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clin Rheumatol 35(12):3069–3073. https://​doi.​org/​10.​1007/​s10067-016-3362-2 CrossRefPubMed
19.
Eriksson JK, Jacobsson L, Bengtsson K, Askling J (2017) Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis 76(2):364–370. https://​doi.​org/​10.​1136/​annrheumdis-2016-209315 CrossRefPubMed
20.
Huang Y-P, Wang Y-H, Pan S-L (2013) Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis—a population-based longitudinal follow-up study. PLoS One 8(5):e64155. https://​doi.​org/​10.​1371/​journal.​pone.​0064155 CrossRefPubMedPubMedCentral
21.
Essers I, Stolwijk C, Boonen A, de Bruin ML, Bazelier MT, de Vries F, van Tubergen A (2016) Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis 75(1):203–209. https://​doi.​org/​10.​1136/​annrheumdis-2014-206147 CrossRefPubMed
22.
Kucuk A, Uğur Uslu A, Icli A, Cure E, Arslan S, Turkmen K, Toker A, Kayrak M (June 2016) The LDL/HDL ratio and atherosclerosis in ankylosing spondylitis. Z Rheumatol 76:58–63. https://​doi.​org/​10.​1007/​s00393-016-0092-4 CrossRef
23.
Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, Rahman MA, Siebert S (2012) No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis—a retrospective cohort study using routine data. Semin Arthritis Rheum 42(2):140–145. https://​doi.​org/​10.​1016/​j.​semarthrit.​2012.​02.​008 CrossRefPubMed
24.
Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, Kiortsis DN, Drosos AA (2014) Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine 81(1):57–63. https://​doi.​org/​10.​1016/​j.​jbspin.​2013.​03.​019 CrossRefPubMed
25.
Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347CrossRefPubMed
26.
Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2):69–75CrossRefPubMed
27.
Del Rincón I, Williams K, Stern MP, Freeman GL, O’leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840CrossRefPubMed
28.
Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406CrossRefPubMed
29.
Salmon JE, Roman MJ (2008) Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 121(10):S3–S8CrossRefPubMedPubMedCentral
30.
Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45(3):283–286CrossRefPubMed
31.
Peters MJL, Smulders Y, Serne E, Dijkmans B, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166CrossRefPubMed
32.
Van Eijk IC, Peters MJL, Serne EH et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 68(3):362–366CrossRefPubMed
33.
Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489. https://​doi.​org/​10.​1136/​annrheumdis-2014-206624 CrossRefPubMedPubMedCentral
34.
Clegg DO (2006) Treatment of ankylosing spondylitis. J Rheumatol Suppl 33(78):24
35.
Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563–2574CrossRefPubMed
36.
McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9):e1001098CrossRefPubMedPubMedCentral
37.
Bolten WW (2006) Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65(1):7–13CrossRefPubMed
38.
Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMed
39.
Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 14(3):R141CrossRefPubMedPubMedCentral
40.
Daïen CI, Duny Y, Barnetche T, Daurès J-P, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868CrossRefPubMed
41.
Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJK, Edwards CJ (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 50(3):518–531CrossRefPubMed
42.
Barnabe C, Martin B, Ghali WA (2011) Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63(4):522–529CrossRef
43.
Tournadre A, Mathieu S, Soubrier M (2016) Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. Ther Adv Musculoskelet Dis 8(5):180–191. https://​doi.​org/​10.​1177/​1759720X16664306​ CrossRefPubMedPubMedCentral
44.
Tiosano S, Yavne Y, Gendelman O, Watad A, Comaneshter D, Shoenfeld Y, Cohen AD, Amital D (2017) Stroke among rheumatoid arthritis patients: does age matter a real-life study. Neuroepidemiology 49(3–4):99–105. https://​doi.​org/​10.​1159/​000481992 CrossRefPubMed
45.
Versini M, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (April 2017) Smoking and obesity in systemic lupus erythematosus: a cross-sectional study. Eur J Clin Investig 47:422–427. https://​doi.​org/​10.​1111/​eci.​12757 CrossRef